# Antineoplaston Therapy in Treating Patients With Brain Tumors

> **NCT00003457** · PHASE2 · COMPLETED · sponsor: **Burzynski Research Institute** · enrollment: 40 (actual)

## Conditions studied

- Refractory Brain Tumors

## Interventions

- **DRUG:** Antineoplaston therapy (Atengenal + Astugenal)

## Key facts

- **NCT ID:** NCT00003457
- **Lead sponsor:** Burzynski Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-07
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003457, "Antineoplaston Therapy in Treating Patients With Brain Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00003457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*